PROTOPIC (tacrolimus) by Leo Pharma is protein, fkbp-12. Approved for kidney transplantation, liver transplantation, heart transplantation and 1 more indications. First approved in 2000.
Drug data last refreshed 19h ago · AI intelligence enriched 2w ago
PROTOPIC (tacrolimus) is a calcineurin inhibitor topical ointment approved in 2000 for treating atopic dermatitis, psoriasis, and other inflammatory and immune-mediated conditions. It works by inhibiting T-lymphocyte activation and proliferation through blockade of calcineurin phosphatase activity, preventing transcription factor translocation and cytokine production. The drug has been used across 21 indications including organ transplantation, autoimmune diseases, and hematologic malignancies.
With LOE approaching and minimal Part D spending, the PROTOPIC brand team faces significant portfolio pressure and likely operates in maintenance-mode with smaller commercial infrastructure than peak-stage products.
protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors…
Worked on PROTOPIC at Leo Pharma? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Dose-Expansion Study of Low Dose Post-Transplant Cyclophosphamide/Tacrolimus/Ruxolitinib for Graft-versus-Host Disease (GVHD) Prophylaxis in Myeloablative Allogeneic Peripheral Blood Stem Cell Transplantation
Neurocognitive Function Changes With Extended-Release Tacrolimus Among Older Kidney Transplant Recipients
A Study to Investigate the Efficacy and Safety of Frexalimab Versus Tacrolimus in Adults Undergoing Kidney Transplantation
Tacrolimus and Risk Factors for Glucose Metabolism Disorders in Kidney Transplant Patients
Real-word Study of the de NOVO Extended-release tacrolimuS in Kidney Transplantation Using an ARTificial Intelligence
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moUpgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moPROTOPIC offers limited career growth given its mature lifecycle stage, approaching LOE, and minimal linked job openings. Roles are primarily commercial and defensive, focused on market maintenance rather than expansion, making it less attractive for ambitious early-career professionals seeking dynamic product exposure.